Search results
Results from the WOW.Com Content Network
Although the use of the term DMARDs was first propagated in rheumatoid arthritis (hence their name), the term has come to pertain to many other diseases, such as Crohn's disease, lupus erythematosus, Sjögren syndrome, immune thrombocytopenic purpura, myasthenia gravis, sarcoidosis, and various others. [citation needed]
A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response.TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma, so TNF inhibitors may be used in their ...
A phase II study of rheumatoid arthritis patients failing to respond to a biologic agent showed little efficacy as compared to placebo, but the drug was well tolerated. In patients with high inflammatory burden, measured by levels of C-reactive protein , ACR20 was achieved by a significantly higher portion of those in the fostamatinib group (42 ...
They are used to treat complex or rare chronic conditions such as cancer, rheumatoid arthritis, hemophilia, H.I.V. [5] psoriasis, [3] inflammatory bowel disease [3] and hepatitis C. [4] [8] In 1990 there were 10 specialty drugs on the market, [9] around five years later nearly 30, [10] by 2008 200, [10] and by 2015 300. [11]
Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases.This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. [23]
Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
Sulfasalazine also appears to be most effective in the short-term treatment of rheumatoid arthritis. [127] Hydroxychloroquine, in addition to its low toxicity profile, is considered effective for treatment of moderate RA symptoms. [128] Agents may be used in combination, however, people may experience greater side effects.
One study modeled that, in the US, the average yearly cost of biological therapy for inflammatory bowel disease was around $36,000. [29] The treatment of inflammatory bowel diseases, with an estimated direct cost of $5.9 billion annually, poses a significant economic burden on the health care system.